
Approved Antivirals: COVID-19, Influenza, Smallpox/Other Poxviruses*



- 22 distinct antiviral compounds have received regulatory approval for COVID-19, Influenza, or Smallpox/Other Poxviruses
- 4 compounds are approved for COVID-19 and Influenza (favipiravir, triazavirin, umifenovir, and enisamium)
- 3 compounds have regulatory authorization by Animal Rule Development or similar mechanism
 - Tecoviramat is approved for Smallpox in U.S. & EU, and Cowpox and Mpox in EU only
 - Brincidofovir for Smallpox in U.S.
 - NIOH-14 for Smallpox in Russia

*As of July 12, 2024; WHO defined Other National Authority (https://www.who.int/publications/m/item/list-of-transitional-wlas)



Antiviral-Indication Expansions: Preclinical & Clinical Compound/Indications

Investigational: Antiviral compounds in clinical phase development for a different virus disease indication. Approved: Antiviral compounds approved for treatment of a different virus disease indication.



- **6** of these antivirals (favipiravir, remdesivir, molnupiravir, amantadine, oseltamivir, & zanamivir) are approved for treatment of COVID-19 and/or Influenza.
 - ► Valganciclovir and cidofovir are approved for treating CMV disease.
- Favipiravir has the most indication expansions under evaluation (9) followed by remdesivir (6).

*As of July 12, 2024



Interested in engaging with us?

We welcome all feedback through <u>our online</u> <u>portal</u>. As with previous listings, developers are invited to submit non-confidential information on their compound candidates. All reports are updated quarterly.

For more information, contact <u>nina@intrepidalliance.org</u>.

intrepidalliance.org



linkedin.com/company/intrepid-alliance

